DUK
37
-3
SO
51
-6
JNPR
59
3
XOM
40
-2
FDX
39
-5
LLY
39
-6
OKE
62
-8
HSY
31
2
CMA
52
-3
ALL
35
-3
AIZ
47
-2
ABBV
59
-3
RL
66
-2
UA
36
-5
AES
31
-9
GLW
52
2
BF.B
29
-2
AME
54
-8
FSLR
57
8
XRAY
22
2
DUK
37
-3
SO
51
-6
JNPR
59
3
XOM
40
-2
FDX
39
-5
LLY
39
-6
OKE
62
-8
HSY
31
2
CMA
52
-3
ALL
35
-3
AIZ
47
-2
ABBV
59
-3
RL
66
-2
UA
36
-5
AES
31
-9
GLW
52
2
BF.B
29
-2
AME
54
-8
FSLR
57
8
XRAY
22
2
Financhill
Back

Celldex Therapeutics 10K Form

Sell
33

CLDX
Celldex Therapeutics

Last Price:
25.39
Seasonality Move:
16.03%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive CLDX News And Ratings

See the #1 stock for the next 7 days that we like better than CLDX

CLDX Financial Statistics

Sales & Book Value

Annual Sales: $6.88M
Cash Flow: $-29.6M
Price / Cash Flow: 0
Annual Sales: $12.28
Price / Book: 2.09

Profitability

EPS (TTM): -2.75000
Net Income (TTM): $-150.22M
Gross Margin: $0
Return on Equity: -28.83%
Return on Assets: -27.22%

Celldex Therapeutics Earnings Forecast

Key Celldex Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 30 years for CLDX is 0.00%.
  • The Selling, General & Administrative Expenses for CLDX have been equal to 449.14% of Gross Profit Margin.
  • The Research & Development expenses have been 1,714.53% of Revenue.
  • The Interest Expense is 0.00% of Operating Income.
  • The Net Earning history of CLDX is -2,054.76% of Total Revenues.
  • Per Share Earnings over the last 38 years have been positive in 22 years.

Celldex Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: CLDX
CUSIP: 15117B
Website: celldex.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 29.36
Quick Ratio: 29.06

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

CLDX Technical Analysis vs Fundamental Analysis

Sell
33
Celldex Therapeutics (CLDX) is a Sell

Is Celldex Therapeutics a Buy or a Sell?